AG
KALV

Algert Global’s KalVista Pharmaceuticals KALV Stock Holding History

Algert Global’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-13,110
Closed -$212K – 1252
2025
Q4 		$212K Buy
+13,110
New +$174K ﹤0.01% 1049
2025
Q1 		– Sell
-10,360
Closed -$88K – 1261
2024
Q4 		$88K Buy
+10,360
New +$107K ﹤0.01% 1126
2023
Q4 		– Sell
-23,250
Closed -$224K – 1191
2023
Q3 		$224K Sell
23,250
-3,040
-12% -$31.1K 0.01% 946
2023
Q2 		$237K Sell
26,290
-2,220
-8% -$20.5K 0.01% 955
2023
Q1 		$224K Buy
+28,510
New +$213K 0.01% 1009
2021
Q1 		– Sell
-12,119
Closed -$230K – 481
2020
Q4 		$230K Sell
12,119
-2,100
-15% -$36K 0.07% 333
2020
Q3 		$179K Buy
14,219
+3,090
+28% +$38.6K 0.06% 325
2020
Q2 		$135K Sell
11,129
-7,700
-41% -$81.9K 0.05% 361
2020
Q1 		$144K Buy
18,829
+4,860
+35% +$65.6K 0.06% 330
2019
Q4 		$249K Sell
13,969
-14,767
-51% -$193K 0.07% 287
2019
Q3 		$333K Buy
28,736
+4,069
+16% +$65.7K 0.12% 202
2019
Q2 		$546K Buy
24,667
+8,076
+49% +$189K 0.2% 161
2019
Q1 		$475K Sell
16,591
-2,750
-14% -$59.6K 0.27% 136
2018
Q4 		$382K Buy
+19,341
New +$389K 0.11% 251

Other funds holding KALV

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Algert Global's KALV Position: Q1 2026 in Review

Algert Global sold out of KalVista Pharmaceuticals (KALV) in Q1 2026, closing a stake of 13,110 shares — an estimated $212K sold.

Algert Global first reported a position in KALV in Q4 2018 and held it in 14 quarters. The position peaked at $546K in Q2 2019. 183 funds tracked by Wall St. Rank hold KALV as of Q1 2026.

  • Algert Global reported no remaining KalVista Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Algert Global sold 13,110 KalVista Pharmaceuticals shares in Q1 2026, an estimated $212K.
  • Algert Global first reported a position in KalVista Pharmaceuticals in Q4 2018 and held it in 14 quarters.
  • Algert Global's KalVista Pharmaceuticals position peaked at $546K in Q2 2019.
  • 183 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2026.

Based on Algert Global's 13F filing for Q1 2026, filed 14 May 2026.